Form 4: Aurinia Pharmaceuticals Director Stock Option Grant

Aurinia Pharmaceuticals Inc. reports a stock option grant to Director Kathleen Goetz, with vesting details and exercise price.

Summary

• Kathleen Goetz, a Director at Aurinia Pharmaceuticals Inc., was granted a stock option.
• The option is for 23,931 shares of common stock.
• The exercise price for these options is $15.67 per share.
• The options are set to vest one year from the date of grant, which is June 4, 2026.
• The options have an expiration date of June 4, 2036.
• This transaction is reported under SEC Form 4, indicating a change in beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a routine event for executive compensation and does not inherently signal positive or negative company performance.

Positives

• Director Kathleen Goetz has been granted stock options, aligning her interests with shareholders.
• The grant of 23,931 options provides potential upside for the director based on the company's stock performance.
• The exercise price of $15.67 suggests a current market value or a valuation at the time of grant that is not significantly above the exercise price.

Risks

• The value of the stock options is contingent on the future performance of Aurinia Pharmaceuticals' stock price.
• If the stock price does not exceed the exercise price of $15.67, the options may not be exercised profitably.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance, with vesting occurring one year from the grant date and an expiration date ten years from the grant date.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biopharmaceutical industry to incentivize leadership and align their financial interests with long-term shareholder value creation.

Related Party Transactions

• The grant of stock options to Director Kathleen Goetz is a related party transaction, as it involves a company insider.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with shareholder interests, potentially leading to decisions that enhance stock value. Dilution is minimal given the number of options relative to typical public float.
• Employees: This filing does not directly impact employees, but it reflects standard compensation practices for senior leadership.
• Management: The options provide a financial incentive for the director to perform well and contribute to the company's success.

Next Steps

• The stock options will vest one year from the grant date (June 4, 2026).
• The options can be exercised anytime between the vesting date and the expiration date (June 4, 2036).

Key Dates

Keywords

Aurinia Pharmaceuticals, AUPH, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Kathleen Goetz